Published in Lab Business Week, December 30th, 2007
Sequoia's first IND was submitted for its' novel HIV protease inhibitor, SPI-256, in February 2007, and ongoing Phase I clinical trials continue to yield favorable results.
"I am very impressed with the accomplishments of the teams at Sequoia. To have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.